# KromaTiD

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kromatid

- Industry: Biotechnology
- Headquarters: Longmont, US
- Website: www.kromatid.com
- Total disclosed funding: $9.3M
- Latest round: Series C (Jul 1, 2025)
- Investors on record: 2

## About

KromaTiD, Inc. specializes in genomic integrity analysis, providing innovative solutions for single-cell visualization and reporting through their proprietary KROMASURE™ Platform, crucial for advancing cell and gene therapy research. Founded in 2007, KromaTiD, Inc. is based in Longmont, US, focusing on genomic integrity analysis. In August 2025, KromaTiD, Inc. raised USD 8 million in series C funding led by returning investor BroadOak Capital Partners, with participation from other unspecified investors. KromaTiD specializes in genomic integrity analysis, focusing on single-cell visualization through its KROMASURE™ Platform. This platform provides insights into chromosomal integrity, structural variants, and transgene mapping, essential for cell and gene therapy research, catering to biotechnology and pharmaceutical sectors globally.KromaTiD's revenue model is driven by B2B transactions, offering services and solutions to biotech firms, pharmaceutical companies, and regulatory bodies. The company engages clients through partnerships that grant access to the KROMASURE™ Platform and genomic analysis services, with a pricing structure that includes project-based fees and subscription models tailored to client needs. The company will use the August 2025 funding to enhance collaborations in genomic structural analysis and gene therapy.

## Funding rounds

- Series C, Jul 1, 2025, $1.5M — BroadOak Capital Partners
- Series A, Sep 30, 2021, $7.9M — First Capital Ventures

## Investors

- First Capital Ventures (https://capitalatlas.ai/funds/first-capital-ventures) — Series A
- BroadOak Capital Partners (https://capitalatlas.ai/funds/broadoak-capital-partners) — Series C